Guo et al. produced PD-1-deficient CAR-T cells using a CRISPR/Cas9 system and demonstrated that the disruption of PD-1 increased the CAR T cell ability to kill HCC cells in vitro and in vivo [98]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.